GYRE
Gyre Therapeutics, Inc.
Biotechnology · Healthcare · United States
4.56
close · 2026-10-30
value
31
cheaper than peers31
quality
75
stronger fundamentals75
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 6.90× | 67 |
| price to book | 4.47× | 38 |
| forward P/E | 75.92× | 10 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 2.1% | 86 |
| return on equity | -17.4% | 72 |
| operating margin | -47.6% | 63 |
| revenue growth | -2.1% | 33 |
4 of 4 measures available
Facts
| market cap | $483M |
| free cash flow | $1.9M |
| employees | 625 |
| first trade | 2006-04-12 |
| next earnings | 2026-08-07 |
| fundamentals updated | 2026-08-19 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 0.02 | 0.05 | -1.41 | 0.03 |
| free cash flow | -$913,000 | -$6.8M | $17.3M | $5.7M |
| net income | $5.0M | $12.1M | -$92.9M | $2.3M |
| revenue | $116.6M | $105.8M | $113.5M | $102.3M |
| unusual items | $2.7M | $7.1M | -$95.7M | $0 |